Long-Term Outcome in Lupus Nephritis
Authors: Robert F. Spiera, Peter Homel, Harry Spiera
Journal: Annals of Internal Medicine (2002)

Letters17 September 2002Long-Term Outcome in Lupus NephritisRobert F. Spiera, MD, Peter Homel, PhD, and Harry Spiera, MDRobert F. Spiera, MDBeth Israel Medical Center; New York, NY 10003Mount Sinai Medical Center; New York, NY 10029Search for more papers by this author, Peter Homel, PhDBeth Israel Medical Center; New York, NY 10003Mount Sinai Medical Center; New York, NY 10029Search for more papers by this author, and Harry Spiera, MDBeth Israel Medical Center; New York, NY 10003Mount Sinai Medical Center; New York, NY 10029Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-137-6-200209170-00018 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail TO THE EDITOR:Illei and colleagues (1) report superior long-term outcomes in patients with lupus nephritis treated with pulse cyclophosphamide with or without pulse methylprednisolone compared with those treated with pulse methylprednisolone alone. Their data also suggest that pulse methylprednisolone combined with cyclophosphamide has additional benefit. The primary outcomes defining treatment failure were need for supplemental immunosuppressive therapy, doubling of serum creatinine concentration, or death.Illei and colleagues' mortality data, however, are intriguing. The investigators previously reported that after 5 years of follow-up, 3 of 55 cyclophosphamide-treated patients had died compared with 0 of 27 patients randomly assigned to pulse ...References1. Illei GG, Austin HA, Crane M, Collins L, Gourley MF, Yarboro CH, et al . Combination therapy with pulse cyclophosphamide plus pulse methylprednisolone improves long-term renal outcome without adding toxicity in patients with lupus nephritis. Ann Intern Med. 2001;135:248-57. [PMID: 11511139] LinkGoogle Scholar2. Gourley MF, Austin HA, Scott D, Yarboro CH, Vaughan EM, Muir J, et al . Methylprednisolone and cyclophosphamide, alone or in combination, in patients with lupus nephritis. A randomized, controlled trial. Ann Intern Med. 1996;125:549-57. [PMID: 8815753] LinkGoogle Scholar Author, Article, and Disclosure InformationAffiliations: Beth Israel Medical Center; New York, NY 10003Mount Sinai Medical Center; New York, NY 10029 PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetailsSee AlsoCombination Therapy with Pulse Cyclophosphamide plus Pulse Methylprednisolone Improves Long-Term Renal Outcome without Adding Toxicity in Patients with Lupus Nephritis Gabor G. Illei , Howard A. Austin III , Marianna Crane , Lee Collins , Mark F. Gourley , Cheryl H. Yarboro , Ellen M. Vaughan , Takashi Kuroiwa , Carol L. Danning , Alfred D. Steinberg , John H. Klippel , James E. Balow , and Dimitrios T. Boumpas Long-Term Outcome in Lupus Nephritis Gabor G. Illei , James E. Balow , and Dimitrios T. Boumpas Metrics Cited BySystemic lupus erythematosus 17 September 2002Volume 137, Issue 6Page: 545KeywordsCyclophosphamideHeart rateImmunosuppressivesIntent to treat analysisLupus nephritisMortalityRelative riskRenal analysisSalvage antiretroviral therapySurvival analysis ePublished: 17 September 2002 Issue Published: 17 September 2002 CopyrightCopyright © 2002 by American College of Physicians. All Rights Reserved.PDF DownloadLoading ...